Jinyu Bio-Technology Co Current Liabilities
The Current Liabilities of Jinyu Bio-Technology Co (600201.SS) as of Oct 27, 2026 is 263.56 M CNY. In the previous year, Current Liabilities was 777.28 M CNY — a change of -66.09% (lower).
Get this data via API
Financial Data API
Current Liabilities
263.56 MCNY
YoY
-66.09%
Last updated:
The Jinyu Bio-Technology Co Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 263.56 MCNY | -66.09% | |
| 777.28 MCNY | -13.96% | |
| 903.35 MCNY | +27.29% | |
| 709.69 MCNY | +5.94% | |
| 669.89 MCNY | -9.57% | |
| 740.75 MCNY | +17.57% | |
| 630.03 MCNY | -34.92% | |
| 968.11 MCNY | -12.77% | |
| 1.11 BCNY | +104.94% | |
| 541.54 MCNY | +14.32% | |
| 473.71 MCNY | -2.45% | |
| 485.60 MCNY | +1.47% | |
| 478.55 MCNY | -39.26% | |
| 787.90 MCNY | +0.79% | |
| 781.73 MCNY | -5.11% | |
| 823.84 MCNY | +20.61% | |
| 683.08 MCNY | +24.35% | |
| 549.32 MCNY | -8.44% | |
| 599.94 MCNY | +45.75% | |
| 411.62 MCNY | -32.01% | |
| 605.41 MCNY | +69.20% | |
| 357.81 MCNY | -6.73% | |
| 383.62 MCNY | +37.05% | |
| 279.92 MCNY | +5.81% | |
| 264.56 MCNY | -7.39% | |
| 285.67 MCNY | +92.84% | |
| 148.14 MCNY | +31.31% | |
| 112.82 MCNY | +7.51% | |
| 104.94 MCNY | -11.06% | |
| 117.99 MCNY | -10.10% | |
| 131.24 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Jinyu Bio-Technology Co Stock analysis
Frequently Asked Questions about Jinyu Bio-Technology Co stock
Current Liabilities of Jinyu Bio-Technology Co is 263.56 M CNY in 2025.
Current Liabilities of Jinyu Bio-Technology Co changed from 777.28 M CNY to 263.56 M CNY, representing a -66.09% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Jinyu Bio-Technology Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth